カテゴリ： 世界, 医療/バイオ, Market Monitor Global

IgA腎症治療のグローバル市場展望 2023年-2029年：副腎皮質ステロイド、免疫抑制剤、ACE・ARB阻害剤

■ 英語タイトル：IgA Nephropathy Treatment Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート（データ管理コード：MMG23LY8800）■ 発行会社/調査会社：Market Monitor Global
■ 商品コード：MMG23LY8800
■ 発行日：2023年7月
■ 調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野：医薬品＆ヘルスケア
■ ページ数：114
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[IgA腎症治療のグローバル市場展望 2023年-2029年：副腎皮質ステロイド、免疫抑制剤、ACE・ARB阻害剤]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査レポートは次の情報を含め、世界のIgA腎症治療市場規模と予測を収録しています。・世界のIgA腎症治療市場：売上、2018年-2023年、2024年-2029年
・世界のIgA腎症治療市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界のIgA腎症治療市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「副腎皮質ステロイド」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

IgA腎症治療のグローバル主要企業は、AstraZeneca、 Johnson & Johnson Private Limited、 Cipla Inc.、 Hikma Pharmaceuticals PLC、 Zydus Cadila、 LEO Pharma A/S、 Fresenius Kabi AG、 Accord Healthcare、 Abbott、 F. Hoffmann-La Roche Ltd.、 Mylan N.V.、 Teva Pharmaceutical Industries Ltd.、 Sanofi、 Novartis AG、 Sun Pharmaceutical Industries Ltd.、 Aurobindo Pharma、 Lupin、 Alembic Pharmaceuticals Limited、 Apotex Incなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、IgA腎症治療のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界のIgA腎症治療市場：タイプ別、2018年-2023年、2024年-2029年
世界のIgA腎症治療市場：タイプ別市場シェア、2022年
・副腎皮質ステロイド、免疫抑制剤、ACE・ARB阻害剤

世界のIgA腎症治療市場：用途別、2018年-2023年、2024年-2029年
世界のIgA腎症治療市場：用途別市場シェア、2022年
・病院、薬局、その他

世界のIgA腎症治療市場：地域・国別、2018年-2023年、2024年-2029年
世界のIgA腎症治療市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業におけるIgA腎症治療のグローバル売上、2018年-2023年
・主要企業におけるIgA腎症治療のグローバル売上シェア、2022年
・主要企業におけるIgA腎症治療のグローバル販売量、2018年-2023年
・主要企業におけるIgA腎症治療のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
AstraZeneca、 Johnson & Johnson Private Limited、 Cipla Inc.、 Hikma Pharmaceuticals PLC、 Zydus Cadila、 LEO Pharma A/S、 Fresenius Kabi AG、 Accord Healthcare、 Abbott、 F. Hoffmann-La Roche Ltd.、 Mylan N.V.、 Teva Pharmaceutical Industries Ltd.、 Sanofi、 Novartis AG、 Sun Pharmaceutical Industries Ltd.、 Aurobindo Pharma、 Lupin、 Alembic Pharmaceuticals Limited、 Apotex Inc

*************************************************************

・調査・分析レポートの概要
IgA腎症治療市場の定義
市場セグメント
世界のIgA腎症治療市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界のIgA腎症治療市場規模
世界のIgA腎症治療市場規模：2022年 VS 2029年
世界のIgA腎症治療市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでのIgA腎症治療の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業のIgA腎症治療製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：副腎皮質ステロイド、免疫抑制剤、ACE・ARB阻害剤
IgA腎症治療のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、薬局、その他
IgA腎症治療の用途別グローバル売上・予測

・地域別市場分析
地域別IgA腎症治療市場規模 2022年と2029年
地域別IgA腎症治療売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
AstraZeneca、 Johnson & Johnson Private Limited、 Cipla Inc.、 Hikma Pharmaceuticals PLC、 Zydus Cadila、 LEO Pharma A/S、 Fresenius Kabi AG、 Accord Healthcare、 Abbott、 F. Hoffmann-La Roche Ltd.、 Mylan N.V.、 Teva Pharmaceutical Industries Ltd.、 Sanofi、 Novartis AG、 Sun Pharmaceutical Industries Ltd.、 Aurobindo Pharma、 Lupin、 Alembic Pharmaceuticals Limited、 Apotex Inc
...

Currently, there are two main methods for the treatment of IgA nephropathy, one is conservative therapy and the other is immunosuppressive therapy.
This report aims to provide a comprehensive presentation of the global market for IgA Nephropathy Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding IgA Nephropathy Treatment. This report contains market size and forecasts of IgA Nephropathy Treatment in global, including the following market information:
Global IgA Nephropathy Treatment Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global IgA Nephropathy Treatment Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five IgA Nephropathy Treatment companies in 2022 (%)
The global IgA Nephropathy Treatment market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Conservative treatment is the first-line treatment for patients without rapidly progressive decline in renal function. Specific measures include blood pressure control, use of RAS blockers, treatment of dyslipidemia (statins), low-salt diet (sodium <2 g/d), weight loss, smoking cessation, and avoidance of nephrotoxic drugs and nonsteroidal anti-inflammatory drugs. Corticosteroids are currently the only immunosuppressive agents with evidence to support their efficacy. In addition, the current evidence shows that mycophenolate mofetil, hydroxychloroquine, tonsillectomy, complement inhibitors and other treatments have a certain effect on IgA nephropathy, but more clinical trials are needed to verify it. MARKET MONITOR GLOBAL, INC (MMG) has surveyed the IgA Nephropathy Treatment manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks. Total Market by Segment: Global IgA Nephropathy Treatment Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units) Global IgA Nephropathy Treatment Market Segment Percentages, by Type, 2022 (%) Corticosteroids Immunosuppressant ACE and ARB Inhibitors Global IgA Nephropathy Treatment Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units) Global IgA Nephropathy Treatment Market Segment Percentages, by Application, 2022 (%) Hospital Pharmacy Other Global IgA Nephropathy Treatment Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units) Global IgA Nephropathy Treatment Market Segment Percentages, By Region and Country, 2022 (%) North America US Canada Mexico Europe Germany France U.K. Italy Russia Nordic Countries Benelux Rest of Europe Asia China Japan South Korea Southeast Asia India Rest of Asia South America Brazil Argentina Rest of South America Middle East & Africa Turkey Israel Saudi Arabia UAE Rest of Middle East & Africa Competitor Analysis The report also provides analysis of leading market participants including: Key companies IgA Nephropathy Treatment revenues in global market, 2018-2023 (Estimated), ($ millions) Key companies IgA Nephropathy Treatment revenues share in global market, 2022 (%) Key companies IgA Nephropathy Treatment sales in global market, 2018-2023 (Estimated), (K Units) Key companies IgA Nephropathy Treatment sales share in global market, 2022 (%) Further, the report presents profiles of competitors in the market, key players include: AstraZeneca Johnson & Johnson Private Limited Cipla Inc. Hikma Pharmaceuticals PLC Zydus Cadila LEO Pharma A/S Fresenius Kabi AG Accord Healthcare Abbott F. Hoffmann-La Roche Ltd. Mylan N.V. Teva Pharmaceutical Industries Ltd. Sanofi Novartis AG Sun Pharmaceutical Industries Ltd. Aurobindo Pharma Lupin Alembic Pharmaceuticals Limited Apotex Inc Outline of Major Chapters: Chapter 1: Introduces the definition of IgA Nephropathy Treatment, market overview. Chapter 2: Global IgA Nephropathy Treatment market size in revenue and volume. Chapter 3: Detailed analysis of IgA Nephropathy Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets. Chapter 6: Sales of IgA Nephropathy Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world. Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. Chapter 8: Global IgA Nephropathy Treatment capacity by region & country. Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry. Chapter 11: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Introduction to Research & Analysis Reports
1.1 IgA Nephropathy Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global IgA Nephropathy Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global IgA Nephropathy Treatment Overall Market Size
2.1 Global IgA Nephropathy Treatment Market Size: 2022 VS 2029
2.2 Global IgA Nephropathy Treatment Revenue, Prospects & Forecasts: 2018-2029
2.3 Global IgA Nephropathy Treatment Sales: 2018-2029
3 Company Landscape
3.1 Top IgA Nephropathy Treatment Players in Global Market
3.2 Top Global IgA Nephropathy Treatment Companies Ranked by Revenue
3.3 Global IgA Nephropathy Treatment Revenue by Companies
3.4 Global IgA Nephropathy Treatment Sales by Companies
3.5 Global IgA Nephropathy Treatment Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 IgA Nephropathy Treatment Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers IgA Nephropathy Treatment Product Type
3.8 Tier 1, Tier 2 and Tier 3 IgA Nephropathy Treatment Players in Global Market
3.8.1 List of Global Tier 1 IgA Nephropathy Treatment Companies
3.8.2 List of Global Tier 2 and Tier 3 IgA Nephropathy Treatment Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global IgA Nephropathy Treatment Market Size Markets, 2022 & 2029
4.1.2 Corticosteroids
4.1.3 Immunosuppressant
4.1.4 ACE and ARB Inhibitors
4.2 By Type – Global IgA Nephropathy Treatment Revenue & Forecasts
4.2.1 By Type – Global IgA Nephropathy Treatment Revenue, 2018-2023
4.2.2 By Type – Global IgA Nephropathy Treatment Revenue, 2024-2029
4.2.3 By Type – Global IgA Nephropathy Treatment Revenue Market Share, 2018-2029
4.3 By Type – Global IgA Nephropathy Treatment Sales & Forecasts
4.3.1 By Type – Global IgA Nephropathy Treatment Sales, 2018-2023
4.3.2 By Type – Global IgA Nephropathy Treatment Sales, 2024-2029
4.3.3 By Type – Global IgA Nephropathy Treatment Sales Market Share, 2018-2029
4.4 By Type – Global IgA Nephropathy Treatment Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global IgA Nephropathy Treatment Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Pharmacy
5.1.4 Other
5.2 By Application – Global IgA Nephropathy Treatment Revenue & Forecasts
5.2.1 By Application – Global IgA Nephropathy Treatment Revenue, 2018-2023
5.2.2 By Application – Global IgA Nephropathy Treatment Revenue, 2024-2029
5.2.3 By Application – Global IgA Nephropathy Treatment Revenue Market Share, 2018-2029
5.3 By Application – Global IgA Nephropathy Treatment Sales & Forecasts
5.3.1 By Application – Global IgA Nephropathy Treatment Sales, 2018-2023
5.3.2 By Application – Global IgA Nephropathy Treatment Sales, 2024-2029
5.3.3 By Application – Global IgA Nephropathy Treatment Sales Market Share, 2018-2029
5.4 By Application – Global IgA Nephropathy Treatment Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global IgA Nephropathy Treatment Market Size, 2022 & 2029
6.2 By Region – Global IgA Nephropathy Treatment Revenue & Forecasts
6.2.1 By Region – Global IgA Nephropathy Treatment Revenue, 2018-2023
6.2.2 By Region – Global IgA Nephropathy Treatment Revenue, 2024-2029
6.2.3 By Region – Global IgA Nephropathy Treatment Revenue Market Share, 2018-2029
6.3 By Region – Global IgA Nephropathy Treatment Sales & Forecasts
6.3.1 By Region – Global IgA Nephropathy Treatment Sales, 2018-2023
6.3.2 By Region – Global IgA Nephropathy Treatment Sales, 2024-2029
6.3.3 By Region – Global IgA Nephropathy Treatment Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America IgA Nephropathy Treatment Revenue, 2018-2029
6.4.2 By Country – North America IgA Nephropathy Treatment Sales, 2018-2029
6.4.3 US IgA Nephropathy Treatment Market Size, 2018-2029
6.4.4 Canada IgA Nephropathy Treatment Market Size, 2018-2029
6.4.5 Mexico IgA Nephropathy Treatment Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe IgA Nephropathy Treatment Revenue, 2018-2029
6.5.2 By Country – Europe IgA Nephropathy Treatment Sales, 2018-2029
6.5.3 Germany IgA Nephropathy Treatment Market Size, 2018-2029
6.5.4 France IgA Nephropathy Treatment Market Size, 2018-2029
6.5.5 U.K. IgA Nephropathy Treatment Market Size, 2018-2029
6.5.6 Italy IgA Nephropathy Treatment Market Size, 2018-2029
6.5.7 Russia IgA Nephropathy Treatment Market Size, 2018-2029
6.5.8 Nordic Countries IgA Nephropathy Treatment Market Size, 2018-2029
6.5.9 Benelux IgA Nephropathy Treatment Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia IgA Nephropathy Treatment Revenue, 2018-2029
6.6.2 By Region – Asia IgA Nephropathy Treatment Sales, 2018-2029
6.6.3 China IgA Nephropathy Treatment Market Size, 2018-2029
6.6.4 Japan IgA Nephropathy Treatment Market Size, 2018-2029
6.6.5 South Korea IgA Nephropathy Treatment Market Size, 2018-2029
6.6.6 Southeast Asia IgA Nephropathy Treatment Market Size, 2018-2029
6.6.7 India IgA Nephropathy Treatment Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America IgA Nephropathy Treatment Revenue, 2018-2029
6.7.2 By Country – South America IgA Nephropathy Treatment Sales, 2018-2029
6.7.3 Brazil IgA Nephropathy Treatment Market Size, 2018-2029
6.7.4 Argentina IgA Nephropathy Treatment Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa IgA Nephropathy Treatment Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa IgA Nephropathy Treatment Sales, 2018-2029
6.8.3 Turkey IgA Nephropathy Treatment Market Size, 2018-2029
6.8.4 Israel IgA Nephropathy Treatment Market Size, 2018-2029
6.8.5 Saudi Arabia IgA Nephropathy Treatment Market Size, 2018-2029
6.8.6 UAE IgA Nephropathy Treatment Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 AstraZeneca
7.1.1 AstraZeneca Company Summary
7.1.2 AstraZeneca Business Overview
7.1.3 AstraZeneca IgA Nephropathy Treatment Major Product Offerings
7.1.4 AstraZeneca IgA Nephropathy Treatment Sales and Revenue in Global (2018-2023)
7.1.5 AstraZeneca Key News & Latest Developments
7.2 Johnson & Johnson Private Limited
7.2.1 Johnson & Johnson Private Limited Company Summary
7.2.2 Johnson & Johnson Private Limited Business Overview
7.2.3 Johnson & Johnson Private Limited IgA Nephropathy Treatment Major Product Offerings
7.2.4 Johnson & Johnson Private Limited IgA Nephropathy Treatment Sales and Revenue in Global (2018-2023)
7.2.5 Johnson & Johnson Private Limited Key News & Latest Developments
7.3 Cipla Inc.
7.3.1 Cipla Inc. Company Summary
7.3.2 Cipla Inc. Business Overview
7.3.3 Cipla Inc. IgA Nephropathy Treatment Major Product Offerings
7.3.4 Cipla Inc. IgA Nephropathy Treatment Sales and Revenue in Global (2018-2023)
7.3.5 Cipla Inc. Key News & Latest Developments
7.4 Hikma Pharmaceuticals PLC
7.4.1 Hikma Pharmaceuticals PLC Company Summary
7.4.2 Hikma Pharmaceuticals PLC Business Overview
7.4.3 Hikma Pharmaceuticals PLC IgA Nephropathy Treatment Major Product Offerings
7.4.4 Hikma Pharmaceuticals PLC IgA Nephropathy Treatment Sales and Revenue in Global (2018-2023)
7.4.5 Hikma Pharmaceuticals PLC Key News & Latest Developments
7.5 Zydus Cadila
7.5.1 Zydus Cadila Company Summary
7.5.2 Zydus Cadila Business Overview
7.5.3 Zydus Cadila IgA Nephropathy Treatment Major Product Offerings
7.5.4 Zydus Cadila IgA Nephropathy Treatment Sales and Revenue in Global (2018-2023)
7.5.5 Zydus Cadila Key News & Latest Developments
7.6 LEO Pharma A/S
7.6.1 LEO Pharma A/S Company Summary
7.6.2 LEO Pharma A/S Business Overview
7.6.3 LEO Pharma A/S IgA Nephropathy Treatment Major Product Offerings
7.6.4 LEO Pharma A/S IgA Nephropathy Treatment Sales and Revenue in Global (2018-2023)
7.6.5 LEO Pharma A/S Key News & Latest Developments
7.7 Fresenius Kabi AG
7.7.1 Fresenius Kabi AG Company Summary
7.7.2 Fresenius Kabi AG Business Overview
7.7.3 Fresenius Kabi AG IgA Nephropathy Treatment Major Product Offerings
7.7.4 Fresenius Kabi AG IgA Nephropathy Treatment Sales and Revenue in Global (2018-2023)
7.7.5 Fresenius Kabi AG Key News & Latest Developments
7.8 Accord Healthcare
7.8.1 Accord Healthcare Company Summary
7.8.2 Accord Healthcare Business Overview
7.8.3 Accord Healthcare IgA Nephropathy Treatment Major Product Offerings
7.8.4 Accord Healthcare IgA Nephropathy Treatment Sales and Revenue in Global (2018-2023)
7.8.5 Accord Healthcare Key News & Latest Developments
7.9 Abbott
7.9.1 Abbott Company Summary
7.9.2 Abbott Business Overview
7.9.3 Abbott IgA Nephropathy Treatment Major Product Offerings
7.9.4 Abbott IgA Nephropathy Treatment Sales and Revenue in Global (2018-2023)
7.9.5 Abbott Key News & Latest Developments
7.10 F. Hoffmann-La Roche Ltd.
7.10.1 F. Hoffmann-La Roche Ltd. Company Summary
7.10.2 F. Hoffmann-La Roche Ltd. Business Overview
7.10.3 F. Hoffmann-La Roche Ltd. IgA Nephropathy Treatment Major Product Offerings
7.10.4 F. Hoffmann-La Roche Ltd. IgA Nephropathy Treatment Sales and Revenue in Global (2018-2023)
7.10.5 F. Hoffmann-La Roche Ltd. Key News & Latest Developments
7.11 Mylan N.V.
7.11.1 Mylan N.V. Company Summary
7.11.2 Mylan N.V. IgA Nephropathy Treatment Business Overview
7.11.3 Mylan N.V. IgA Nephropathy Treatment Major Product Offerings
7.11.4 Mylan N.V. IgA Nephropathy Treatment Sales and Revenue in Global (2018-2023)
7.11.5 Mylan N.V. Key News & Latest Developments
7.12 Teva Pharmaceutical Industries Ltd.
7.12.1 Teva Pharmaceutical Industries Ltd. Company Summary
7.12.2 Teva Pharmaceutical Industries Ltd. IgA Nephropathy Treatment Business Overview
7.12.3 Teva Pharmaceutical Industries Ltd. IgA Nephropathy Treatment Major Product Offerings
7.12.4 Teva Pharmaceutical Industries Ltd. IgA Nephropathy Treatment Sales and Revenue in Global (2018-2023)
7.12.5 Teva Pharmaceutical Industries Ltd. Key News & Latest Developments
7.13 Sanofi
7.13.1 Sanofi Company Summary
7.13.2 Sanofi IgA Nephropathy Treatment Business Overview
7.13.3 Sanofi IgA Nephropathy Treatment Major Product Offerings
7.13.4 Sanofi IgA Nephropathy Treatment Sales and Revenue in Global (2018-2023)
7.13.5 Sanofi Key News & Latest Developments
7.14 Novartis AG
7.14.1 Novartis AG Company Summary
7.14.2 Novartis AG Business Overview
7.14.3 Novartis AG IgA Nephropathy Treatment Major Product Offerings
7.14.4 Novartis AG IgA Nephropathy Treatment Sales and Revenue in Global (2018-2023)
7.14.5 Novartis AG Key News & Latest Developments
7.15 Sun Pharmaceutical Industries Ltd.
7.15.1 Sun Pharmaceutical Industries Ltd. Company Summary
7.15.2 Sun Pharmaceutical Industries Ltd. Business Overview
7.15.3 Sun Pharmaceutical Industries Ltd. IgA Nephropathy Treatment Major Product Offerings
7.15.4 Sun Pharmaceutical Industries Ltd. IgA Nephropathy Treatment Sales and Revenue in Global (2018-2023)
7.15.5 Sun Pharmaceutical Industries Ltd. Key News & Latest Developments
7.16 Aurobindo Pharma
7.16.1 Aurobindo Pharma Company Summary
7.16.2 Aurobindo Pharma Business Overview
7.16.3 Aurobindo Pharma IgA Nephropathy Treatment Major Product Offerings
7.16.4 Aurobindo Pharma IgA Nephropathy Treatment Sales and Revenue in Global (2018-2023)
7.16.5 Aurobindo Pharma Key News & Latest Developments
7.17 Lupin
7.17.1 Lupin Company Summary
7.17.2 Lupin Business Overview
7.17.3 Lupin IgA Nephropathy Treatment Major Product Offerings
7.17.4 Lupin IgA Nephropathy Treatment Sales and Revenue in Global (2018-2023)
7.17.5 Lupin Key News & Latest Developments
7.18 Alembic Pharmaceuticals Limited
7.18.1 Alembic Pharmaceuticals Limited Company Summary
7.18.2 Alembic Pharmaceuticals Limited Business Overview
7.18.3 Alembic Pharmaceuticals Limited IgA Nephropathy Treatment Major Product Offerings
7.18.4 Alembic Pharmaceuticals Limited IgA Nephropathy Treatment Sales and Revenue in Global (2018-2023)
7.18.5 Alembic Pharmaceuticals Limited Key News & Latest Developments
7.19 Apotex Inc
7.19.1 Apotex Inc Company Summary
7.19.2 Apotex Inc Business Overview
7.19.3 Apotex Inc IgA Nephropathy Treatment Major Product Offerings
7.19.4 Apotex Inc IgA Nephropathy Treatment Sales and Revenue in Global (2018-2023)
7.19.5 Apotex Inc Key News & Latest Developments
8 Global IgA Nephropathy Treatment Production Capacity, Analysis
8.1 Global IgA Nephropathy Treatment Production Capacity, 2018-2029
8.2 IgA Nephropathy Treatment Production Capacity of Key Manufacturers in Global Market
8.3 Global IgA Nephropathy Treatment Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 IgA Nephropathy Treatment Supply Chain Analysis
10.1 IgA Nephropathy Treatment Industry Value Chain
10.2 IgA Nephropathy Treatment Upstream Market
10.3 IgA Nephropathy Treatment Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 IgA Nephropathy Treatment Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • IgA腎症治療薬のグローバル市場展望 2023年-2029年：第I相、第II相、第III相
  • 皮膚糸状菌症治療のグローバル市場展望 2023年-2029年：Rx、OTC
  • サラセミア治療のグローバル市場展望 2023年-2029年：DFO、DFP、DFX、その他
  • 呼吸器疾患治療のグローバル市場展望 2023年-2029年：吸入＆点鼻薬、経口薬、その他
  • レストレスレッグス症候群治療のグローバル市場展望 2023年-2029年：一次性レストレスレッグス症候群、二次性レストレスレッグス症候群
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MMG23LY8800 )"IgA腎症治療のグローバル市場展望 2023年-2029年：副腎皮質ステロイド、免疫抑制剤、ACE・ARB阻害剤" (英文：IgA Nephropathy Treatment Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。